Reference Center for Inherited Metabolic Diseases, AP-HP, Robert Debré Hospital, University Paris Diderot-Sorbonne Paris Cité, Paris, France.
INSERM U1141, Paris, France.
J Med Genet. 2017 Dec;54(12):843-851. doi: 10.1136/jmedgenet-2017-104903. Epub 2017 Sep 27.
Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) is a multisystem inborn error of metabolism.
To better characterise the natural history of PMM2-CDG.
Medical charts of 96 patients with PMM2-CDG (86 families, 41 males, 55 females) were retrospectively reviewed. Data on clinical, laboratory and molecular parameters at diagnosis were analysed. Follow-up data at last examination were reported for 25 patients.
The patients were born between 1963 and 2011. Diagnosis of PMM2-CDG was made at a mean (SD) age of 6.8 (8.5) years. The presenting signs were mostly neurological (hypotonia, intellectual disability, cerebellar syndrome) and observed in almost all the patients. A total of 38 patients (14 males, 24 females) exhibited, in addition to neurological signs, visceral features including at least one of these: feeding difficulty requiring a nutritional support (n=23), cardiac features (n=20; pericarditis: 14, cardiac malformation: 9, cardiomyopathy: 2), hepato-gastrointestinal features (n=12; chronic diarrhoea: 7, protein-losing enteropathy: 1, ascites: 3, liver failure: 1, portal hypertension: 1), kidney features (n=4; nephrotic syndrome: 2, tubulopathy: 2) and (n=1). Twelve patients died at a mean age of 3.8 years (especially from pericarditis and other cardiac issues). Laboratory abnormalities mostly included elevated transaminases and abnormal coagulation parameters. High thyreostimulin levels, hypocholesterolemia, hypoalbuminemia and elevated transaminases were associated with the visceral phenotype. Besides the common Arg141His variant harboured by half of the patients, 45 different variants were observed.
PMM2-CDG clinical phenotype is heterogeneous in terms of clinical course, with no clear division between neurological and visceral presentations.
磷酸甘露糖变位酶 2-先天性糖基化障碍(PMM2-CDG)是一种多系统先天性代谢缺陷。
更好地描述 PMM2-CDG 的自然病史。
回顾性分析了 96 例 PMM2-CDG 患者(86 个家系,41 名男性,55 名女性)的病历。分析了诊断时的临床、实验室和分子参数数据。报告了最后一次检查时 25 例患者的随访数据。
患者出生于 1963 年至 2011 年之间。PMM2-CDG 的诊断平均年龄为 6.8(8.5)岁。主要表现为神经症状(肌张力低下、智力障碍、小脑综合征),几乎所有患者均有此表现。共有 38 例患者(14 名男性,24 名女性)除了神经症状外,还存在内脏表现,至少有以下一种表现:需要营养支持的喂养困难(23 例)、心脏表现(20 例;心包炎:14 例,心脏畸形:9 例,心肌病:2 例)、肝-胃肠表现(12 例;慢性腹泻:7 例,蛋白丢失性肠病:1 例,腹水:3 例,肝功能衰竭:1 例,门静脉高压:1 例)、肾脏表现(4 例;肾病综合征:2 例,肾小管病:2 例)和(1 例)。12 例患者平均年龄 3.8 岁死亡(主要死于心包炎和其他心脏问题)。实验室异常主要包括转氨酶升高和凝血参数异常。高甲状腺刺激素水平、胆固醇降低、低白蛋白血症和转氨酶升高与内脏表型有关。除了一半患者携带的常见 Arg141His 变异外,还观察到 45 种不同的变异。
PMM2-CDG 的临床表现在临床过程中具有异质性,无明显的神经和内脏表现之分。